Magenta therapeutics appoints michael vasconcelles, m.d. to the board of directors

Cambridge, mass., aug. 17, 2022 (globe newswire) -- magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed michael vasconcelles, m.d. to its board of directors. dr. vasconcelles will also serve on the company's r&d committee and nominating and corporate governance committee.
DNTH Ratings Summary
DNTH Quant Ranking